Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2022-03 Issue:10328 Volume:399 Page:945-955
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Craig Timothy,Magerl Markus,Levy Donald S,Reshef Avner,Lumry William R,Martinez-Saguer Inmaculada,Jacobs Joshua S,Yang William H,Ritchie Bruce,Aygören-Pürsün Emel,Keith Paul K,Busse Paula,Feuersenger Henrike,Pawaskar Dipti,Jacobs Iris,Pragst Ingo,Doyle Mittie K

Funder

CSL Behring

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency;Zotter;Orphanet J Rare Dis,2014

2. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients;Agostoni;Medicine (Baltimore),1992

3. The international WAO/EAACI guideline for the management of hereditary angioedema-the 2017 revision and update;Maurer;Allergy,2018

4. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema;Busse;J Allergy Clin Immunol Pract,2021

5. The elusive physiologic role of factor XII;Schmaier;J Clin Invest,2008

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10

2. Uncovering a novel SERPING1 pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema;Orphanet Journal of Rare Diseases;2024-09-13

3. Développement clinique des thérapeutiques anti-facteur XII ciblant la thrombo-inflammation;La Revue de Médecine Interne;2024-08

4. Current and Emerging Therapeutics in Hereditary Angioedema;Immunology and Allergy Clinics of North America;2024-08

5. Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood;Blood Advances;2024-06-12